We're moving beyond rinse with salt water and hope. The US oral mucositis market forecast predicts that targeted therapies will be a major growth area. Think: mouthwashes that contain cytokines (to promote healing), or gels that release drugs in response to pH changes (acidic = pain = need for medication). Also, probiotics that compete with pathogenic bacteria — early studies show they can reduce mucositis severity.

What's in the pipeline? Cryotherapy is cheap and effective, but adherence is low (holding ice chips for 30 minutes is tough). The US oral mucositis market analysis notes that the fastest‑growing segment is supportive care, not just drugs — things like nutritional counselling, speech therapy, and psychological support. Because mucositis affects quality of life, not just survival.

But research is underfunded. Oral mucositis is seen as a side effect, not a disease. That's changing, but slowly.

The message: if you're a researcher, study mucositis. If you're a patient, join a clinical trial. And if you're a philanthropist, fund this area. It affects millions, and better treatments are desperately needed.